ImPassion130 Trial Outcomes

ImPassion130 Trial Outcomes
Don Photo

3 years 204 Views
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center shares the results of ImPassion130, a phase III study adding atezolizumab to the 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative breast cancer (TNBC).